Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate OROS in Obese Type 2 Diabetic Subjects
NCT00231647Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Feb 2004
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing Topiramate OROS with Placebo (2 arms). Primary endpoint: Percent change in body weight from baseline to Week 16. Started Feb 2004; status: completed.
02
Drugs
topiramate
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00231647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00231647.